Oral tirzepatide Oral tirzepatide is in advanced development and early data suggests it may achieve weight loss results closer to injectable tirzepatide than oral semaglutide achieves relative to its injectable counterpart
In addition, his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Terns Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes
Low dead space syringes reduce retention to 0.003 ml or less, a reduction of over 96%
But, Schacht notes, this wouldnt explain why these drugs have an effect on noncaloric substances, like nicotine and cocaine